{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:48:47Z","timestamp":1775278127415,"version":"3.50.1"},"reference-count":20,"publisher":"The Fukushima Society of Medical Science","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2025]]},"DOI":"10.5387\/fms.25-00013","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:08:29Z","timestamp":1761170909000},"page":"109-120","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating preoperative gemcitabine-based chemoradiation for resectable and borderline resectable pancreatic cancer: a phase 1 study"],"prefix":"10.5387","volume":"72","author":[{"given":"Naoya","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kenjo","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhide","family":"Ishigame","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Kofunato","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichiro","family":"Haga","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Tsukida","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayasu","family":"Azuma","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Marubashi","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin, <b>73<\/b>(3):233-254, 2023.","DOI":"10.3322\/caac.21772"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, <i>et al.<\/i> Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas:The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol, <b>8<\/b>(9):1263-1270, 2022.","DOI":"10.1001\/jamaoncol.2022.2319"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, <i>et al.<\/i> Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Jpn J Clin Oncol, <b>49<\/b>(2):190-194, 2019.","DOI":"10.1093\/jjco\/hyy190"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takahashi S, Ohno I, Ikeda M, Konishi M, Kobayashi T, Akimoto T, <i>et al.<\/i> Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer:A Phase II Open-label Multicenter Prospective Trial (JASPAC05). Annals of surgery, <b>276<\/b>(5):e510-e517, 2022.","DOI":"10.1097\/SLA.0000000000004535"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, <i>et al.<\/i> Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer:Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol, <b>38<\/b>(16):1763-1773, 2020.","DOI":"10.1200\/JCO.19.02274"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sugiura T, Toyama H, Fukutomi A, Asakura H, Takeda Y, Yamamoto K, <i>et al.<\/i> Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04). Journal of hepato-biliary-pancreatic sciences, <b>30<\/b>(11):1249-1260, 2023.","DOI":"10.1002\/jhbp.1353"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gao S, Zhu X, Shi X, Cao K, Bian Y, Jiang H, <i>et al.<\/i> Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer:study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol, <b>14<\/b>(1):52, 2019.","DOI":"10.1186\/s13014-019-1254-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, <i>et al.<\/i> Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4):a multicentre, open-label, randomised, phase 3 trial. Lancet, <b>389<\/b>(10073):1011-1024, 2017.","DOI":"10.1016\/S0140-6736(16)32409-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, <i>et al.<\/i> Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer:A Prospective, Randomized, Open-label, Multicenter Phase 2\/3 Trial. Annals of surgery, <b>268<\/b>(2):215-222, 2018.","DOI":"10.1097\/SLA.0000000000002705"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, <i>et al.<\/i> Borderline resectable pancreatic cancer:the importance of this emerging stage of disease. Journal of the American College of Surgeons, <b>206<\/b>(5):833-846;discussion 46-8, 2008.","DOI":"10.1016\/j.jamcollsurg.2007.12.020"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, <i>et al.<\/i> Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg, <b>105<\/b>(8):946-958, 2018.","DOI":"10.1002\/bjs.10870"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takahashi H, Akita H, Tomokuni A, Kobayashi S, Ohigashi H, Fijiwara Y, <i>et al.<\/i> Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer:Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence. Annals of surgery, <b>264<\/b>(6):1091-1097, 2016.","DOI":"10.1097\/SLA.0000000000001547"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. van Dongen JC, Suker M, Versteijne E, Bonsing BA, Mieog JSD, de Vos-Geelen J, <i>et al.<\/i> Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). Annals of surgery, <b>275<\/b>(5):979-984, 2022.","DOI":"10.1097\/SLA.0000000000004313"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, <i>et al.<\/i> A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma:PREP-01 study. Journal of gastroenterology, <b>54<\/b>(2):194-203, 2019.","DOI":"10.1007\/s00535-018-1506-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, <i>et al.<\/i> Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Annals of surgery, <b>258<\/b>(6):1040-1050, 2013.","DOI":"10.1097\/SLA.0b013e31829b3ce4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Oba A, Del Chiaro M, Satoi S, Kim SW, Takahashi H, Yu J, <i>et al.<\/i> New criteria of resectability for pancreatic cancer:A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Journal of hepato-biliary-pancreatic sciences, <b>29<\/b>(7):725-731, 2022.","DOI":"10.1002\/jhbp.1049"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Birrer DL, Golcher H, Casadei R, Haile SR, Fritsch R, Hussung S, <i>et al.<\/i> Neoadjuvant Therapy for Resectable Pancreatic Cancer:A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Annals of surgery, <b>274<\/b>(5):713-720, 2021.","DOI":"10.1097\/SLA.0000000000005126"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, <i>et al.<\/i> Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer:results of the first prospective randomized phase II trial. Strahlenther Onkol, <b>191<\/b>(1):7-16, 2015.","DOI":"10.1007\/s00066-014-0737-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, <i>et al.<\/i> Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15):a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol, <b>3<\/b>(6):413-423, 2018.","DOI":"10.1016\/S2468-1253(18)30081-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. de Geus SWL, Sachs TE. A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer. Ann Surg Oncol, <b>30<\/b>(6):3427-3436, 2023.","DOI":"10.1245\/s10434-023-13281-1"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/72\/2\/72_25-00013\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:53:29Z","timestamp":1775274809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/72\/2\/72_25-00013\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.25-00013","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25-00013"}}